Abstract CT125: Evaluation of potential drug-drug interactions (DDIs) between futibatinib and CYP3A inhibitors/inducers, CYP3A substrates, or proton pump inhibitors (PPIs)
已完结
20
由 YAN 发布于 2025/12/15 14:05:00
DOI:10.1158/1538-7445.AM2021-CT125
作者：I. Yamamiya,?John Laabs,?A. Hunt,?T. Takenaka,?D. Sonnichsen,?Mark Mina,?Yaohua He,?K. Benhadji
文献类型：期刊论文
补充材料：只需要正文
作者：I. Yamamiya,?John Laabs,?A. Hunt,?T. Takenaka,?D. Sonnichsen,?Mark Mina,?Yaohua He,?K. Benhadji
文献类型：期刊论文
补充材料：只需要正文
American Association for Cancer Research (AACR)
上一个求助:
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:
ElsevierQuantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:ElsevierQuantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance
京公网安备 11010802042870号
